GlassScriptPhysician profile
Linda M Toth
NPI 1184965329
$3,687.39
in general payments reported to CMS, 2019-2025
27 companies · $38.97 in 2025
The $38.97 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,839 · 2022: $1,677 · 2023: $83.74 · 2024: $48.50 · 2025: $38.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $171.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $670.40 | 2021-2022 | |
| Glaxosmithkline, LLC. | $559.47 | 2021-2023 | Trelegy Ellipta |
| Amgen INC. | $326.84 | 2021-2022 | |
| Abbvie INC. | $282.58 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $255.17 | 2021-2022 | |
| Grifols USA, LLC | $237.95 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.46 | 2021-2022 | |
| Genzyme Corporation | $202.29 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $139.18 | 2021 | |
| Optinose US, INC. | $128.72 | 2021-2022 | |
| Covis Pharma Gmbh | $101.78 | 2021-2022 | |
| Kaleo, INC. | $100.06 | 2021-2022 | |
| Alk-Abello, INC | $68.02 | 2021 | |
| Pfizer INC. | $67.60 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.33 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $48.50 | 2024 | Epclusa |
| Seqirus USA INC | $40.06 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $36.94 | 2021 | |
| Currax Pharmaceuticals LLC | $24.46 | 2021 | |
| Supernus Pharmaceuticals, INC. | $23.41 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.35 | 2023 | Glassia |
| Upsher-Smith Laboratories LLC | $20.61 | 2022 | |
| Merck Sharp & Dohme LLC | $17.27 | 2021 | |
| Nabriva Therapeutics, Plc | $16.14 | 2021 | |
| Medline Industries LP | $15.47 | 2023 | |
| Impel Pharmaceuticals INC. | $12.79 | 2023 | Trudhesa |
| Genentech USA, INC. | $5.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Toth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.